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Repetitive Transcranial Magnetic Stimulation (rTMS) is as a promising therapeutic tool for 
major depressive disorder. However, the degree of clinical improvement following rTMS 
treatment still remains questionable. This pilot study aimed at investigating potential working 
mechanisms of rTMS by examining the effects on attentional processing towards negative 
information, a proposed underlying cognitive vulnerability factor for depression. The 
antidepressant effect of high-frequency (10 Hz) rTMS over the left dorsolateral prefrontal 
cortex and possible effects on the inhibitory processing of emotional information was 
assessed in a sample of fourteen depressed patients immediately after the first stimulation 
session and at the end of a two week treatment period. One session of rTMS caused neither 
significant self-reported mood changes, nor improvements in inhibitory control towards 
negative information. After a 10-day treatment period, nine out of our fourteen patients 
demonstrated significant mood improvements, as indexed by a reduction of more than 50 % 
on the Hamilton depression rating scale. Responders also demonstrated significant 
improvements in the inhibitory processing of negative information. This study contributed to 
the existing evidence of the antidepressant effect of rTMS in the treatment of depression and 
additionally was able to demonstrate improvements in underlying deficiencies in inhibitory 


















Because of its high prevalence and impact on quality of life, major depressive disorder 
presents a serious public health concern.  Although several therapeutic interventions have 
proven their effectiveness, some depressed patients (10 up to 20 %) receiving antidepressant 
medication are partially or totally resistant to treatment (Greenberg et al., 2004). For this 
group of drug-resistant patients alternative and effective therapeutic options are therefore 
required. Over the last decade, the application of repetitive Transcranial magnetic stimulation 
(rTMS) has been proposed as a new promising therapeutic tool for depressive disorder 
(Rachid and Bertschy, 2006). This non-invasive technique causes disruptions in brain activity 
by delivering strong magnetic pulses to the cortex that pass through the skull and depolarize 
the underlying neurons of particular areas in the brain (George et al., 2002).  
To date, there has been a flourishing literature on the investigation of possible mood 
effects of rTMS. Several research groups have provided support for the beneficial 
antidepressant effect of focal left dorsolateral prefrontal (DLPFC) rTMS in patients with 
medication-resistant depression. More specifically, improvements in scores on the Hamilton 
Depression Rating Scale (HAMD: Hamilton, 1960) were demonstrated after two weeks of 
daily stimulation, which were superior to placebo rTMS treatment (McNamara et al., 2001; 
Holtzheimer et al., 2002; Kozel and George, 2002; Avery et al., 2006; Bortolomasi et al., 
2007). However, despite these promising results, a number of recent studies were unable to 
replicate the above effects, emphasizing that the degree of clinical improvement still remains 
questionable (Padberg et al., 1999; Martis et al., 2003; Fabre et al., 2004; Couturier, 2005; 
Loo and Mitchell, 2005; Schulze-Rauschenbach et al., 2005).  
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In order to elucidate the above inconsistencies, research should aim at identifying 
potential underlying mechanisms responsible for the observed mood effects, for instance by 
investigating accompanying changes in cognitive functioning and information processing.  
To date, potential effects of rTMS treatment on cognitive functioning have been primarily 
evaluated in light of safety concerns (Triggs et al., 1999; Martis et al., 2003). So far, no 
adverse effect on cognitive performance was found (e.g. Shajahan et al., 2002). Studies 
measuring cognitions using neuropsychological batteries even indicated significant 
improvements in response speed, procedural learning, verbal and visuospatial memory and 
verbal fluency (Padberg et al., 1999; Little et al., 2000; Speer et al., 2001; Martis et al., 2003; 
Fabre et al., 2004; Hausmann et al., 2004; O'Conner et al., 2005; Schulze-Rauschenbach et al., 
2005).  
So far, however, no study has specifically focussed on examining the effects of rTMS 
treatment on specific cognitive dysfunctions in the processing of emotional material. This is 
puzzling given the clinical and theoretical relevance of the question. Cognitive theories of 
depression have repeatedly emphasized the role of a biased processing of emotional 
information in the development and maintenance of depression (Beck et al., 1979; Clark et al., 
1999; Beevers, 2005), with recent empirical studies reliably demonstrating a general cognitive 
inflexibility or inability to inhibit or to disengage from intrusive, irrelevant and negative 
information, leading to recurrent and remaining patterns of negative thoughts and feelings 
(Koster et al., 2005; Mogg and Bradley, 2005; Goeleven et al., 2006; Joormann, 2006; 
Leyman et al., 2007). In line with these findings, recent functional imaging studies have 
shown disruptions in the prefrontal activation patterns of depressive patients (Mayberg, 1997, 
2007; Drevets, 2000; Leppänen, 2006), brain regions found to be important in the 
implementation of top-down attentional control (MacDonald et al., 2000).  
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Because focal rTMS can be used to affect neurotransmission and activation patterns 
within these prefrontal regions (Luborzewski et al., 2007), it may also cause changes in the 
inhibitory processing of emotional information, which in turn might be an important 
underlying mechanism causing secondary mood improvement.  
Facing this important, but still unanswered research question, the aim of the present pilot 
study was threefold.  
First, this study examined the immediate effects of a single rTMS session over the left 
dorsolateral prefrontal cortex (DLPFC) on the inhibitory processing of emotional information 
and mood in treatment-resistant depressive patients during an initial sham-controlled phase. 
The Negative Affective Priming task (NAP), a well-established experimental paradigm that 
enables the measurement of the strength of inhibitory processes towards emotional 
information (Wentura, 1999; Joormann, 2004), was used before and after rTMS. Because 
recent studies within samples of healthy volunteers have demonstrated that one session of 
rTMS can induce changes in top-down attentional control (Vanderhasselt et al., 2006a, 2007) 
and in the inhibition of negative information (Leyman et al., in press), we hypothesized that 
rTMS would also result in immediate improvements in inhibitory control over negative 
information in a depressive patient sample. Because improvements in cognitive control in 
healthy volunteers were not accompanied by acute mood elevations, the latter might be a 
secondary-order effect only appearing after multiple treatment sessions. 
Secondly, the present study also investigated the antidepressive effect of a series of 10 
high-frequency (HF) rTMS sessions in a following open trial. Based on previous studies, 
demonstrating beneficial mood effects after two weeks of rTMS treatment (eg. Avery et al., 
2006), in the present study, improvements in depressive symptoms were also expected. 
Finally, the third aim of this study was to investigate improvements in the inhibitory 
processing of emotional information after rTMS treatment. To our knowledge, this study is 
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the first examining potential changes in the inhibitory control over negative information after 
two weeks of stimulation, yet, a possible cognitive vulnerability factor underlying depressive 




Fourteen depressed, right-handed patients were selected to participate in this study 
protocol, which was approved by the local institutional ethics committee of the Academic 
Hospital (UZ) of the Free University of Brussels and which is in accordance with the latest 
version of the Declaration of Helsinki.  
Prior to inclusion in the study, subjects were carefully screened. All patients met DSM-IV 
criteria for a current major depressive episode with melancholic features based on the Mini 
International Neuropsychiatric Interview; a structured clinical interview performed by a 
trained psychiatrist (MINI) (Pinninti et al., 2003). Six patients reported having a first 
depressive episode and eight of them had recurrent depressive episodes. Thirteen patients 
were antidepressant non-responders, ranging in degrees of treatment resistance (TR). Based 
on the proposed TR staging by Thase and Rush (1997), ten patients could be classified within 
stage III of TR (i.e. failure of at least two trials of a major class of antidepressants plus failure 
of an adequate trial of tricyclic antidepressants); three patients were classified into stage V of 
TR (i.e. failure of a course of bilateral electroconvulsive therapy). For one patient this was the 
first treatment trial after one year of depression. All included patients underwent a washout of 
antidepressant medication, monitored by a psychiatrist. At the time of initiation of rTMS 
treatment, all patients had to be free of anti-depressant pharmacotherapy for at least 2 weeks 
(minimal 3 weeks for those on Fluoxetine). Only five patients reported the use of anxiolytic 
agents during treatment (Alprazolam, Flunitrazepam, Clorazepate) and were kept on a steady 
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dose, whereas nine patients were completely medication free. Importantly, during the rTMS 
treatment period, all included patients had regular contact with a psychiatrist to evaluate 
possible deterioration of their mood, but none were receiving additional psychotherapy. 
For additional confirmation of diagnosis and assessment of symptom severity prior to 
rTMS treatment, the 17-item Hamilton depression rating scale was administered (HAMD) 
(Hamilton, 1960; D’haenen and Verhoeven, 1989), a clinical interview with acceptable 
validity and reliability reports (Ohara and Rehm, 1983). All participants also completed the 
Beck Depression Inventory (BDI) (Beck et al., 1961; Bouman et al., 1985), a 21- item, self-
report measure of the severity of depressive symptoms, with good reliability and validity 
reports. Relevant demographic and clinical patient characteristics are summarized in Table 1. 
 In order to meet safety criteria for HF-rTMS (Wassermann, 1998), patients also 
underwent a thorough physical and neurological (EEG/MRI) examination. Exclusion criteria 
were a history of epileptic seizures and neurosurgical interventions, having a pacemaker or 
other metal or magnetic implants and being pregnant.  
Finally, all subjects received a complete description of the procedure of the study and 
provided written informed consent. 
 
2.2. Study design 
Patients underwent 10 sessions of HF-rTMS at the left DLPFC within a period of two weeks 
(5 days a week). At the beginning of this open treatment trial, each subject also received one 
placebo (sham) rTMS stimulation session, separated one day from the first active stimulation 
session. This phase was a randomized crossover, single-blind design allowing examination of 
short-term, specific rTMS effects in depressive patients.  
Potential mood changes were assessed before (Tpre), immediately after (Tpost) and 30 min after 
(Tpost30) terminating the first rTMS (real/sham) session, using visual analogue scales. 
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Antidepressant effects of two weeks of rTMS treatment were investigated using the HAMD 
and BDI. Inhibitory processing of emotional information was measured before (Tpre) and 
thirty minutes after (Tpost30) terminating the first rTMS (real/sham) session, and at the end of 
the rTMS treatment period (Tposttreatment).Because this study is part of a larger project 
investigating the influence of rTMS on different neuro-cognitive markers, an additional task 
was also administered that was not used for the purposes of the present study. This additional 
measure was a non-emotional task, tapping on different cognitive aspects compared to the 
task used in the present study (for more information see Vanderhasselt et al., in press). All 
measures were always presented in the same order for all participants.  
 
2.3. Repetitive Transcranial Magnetic Stimulation (rTMS) 
For the application of rTMS we used a Magstim high-speed magnetic stimulator (Magstim 
Company Limited, Wales, UK) connected to a figure-eight-shaped coil. Before stimulation, 
the identification of the precise stimulation location of the left DLPFC (Brodmann area 9/46) 
was determined for each subject using Magnetic Resonance Imaging (MRI) non-stereotactic 
guidance. More specifically, to obtain individual anatomical information, all subjects 
underwent a T1-weighted MRI of the brain (3D-TFE, voxel size 1x1x1 mm) using a 1.5T 
Intera MRI scanner (Philips, Best, The Netherlands). All post processing was done on a 
viewforum console. Next, the left DLPFC was located visually on the 3D surface rendering of 
the brain based on the subjects’ known gyral morphology, marking the middle part of the 
median prefrontal gyrus as the centre of the left DLPFC (Brodmann 9/46). The corresponding 
coil position was marked by determining the perpendicular projection of this point on the 
scalp. This coil position was held fixed for each rTMS session. Secondly, a stimulation 
intensity of 110% of the subject’s motor threshold of the right abductor pollicis brevis muscle 
was determined using EMG.  
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In each high-frequency stimulation session (10 Hz), subjects received forty trains of 3.9 s 
duration, separated by an intertrain interval of 26.1 s (1560 pulses per session). During sham 
stimulation, the coil was placed at an angle of 90°, resting on the scalp with only one edge.  
During stimulation, all subjects wore earplugs. Before and during stimulation subjects 
were blindfolded in order to ensure that the altering of the orientation of the coil with respect 
to the scalp in the placebo condition was effectively blinded.  
 
2.4. Clinical mood assessment 
Apart from the assessment of severity of depression symptoms at baseline, the HAMD 
and BDI were also administered at the end of the rTMS treatment period. In order to evaluate 
temporary changes in mood, subjects were asked to rate their subjective mood state using five 
horizontal 100 mm visual analogue scales (VAS) providing measures of sadness, fatigue, 
tension, anger and vigour (Mccormack et al., 1988). 
 
2.5. The Negative Affective Priming Task 
Inhibitory processing of emotional information was measured using the Negative 
Affective Priming (NAP) task (Wentura, 1999; Joormann, 2004). During the administration of 
the NAP task, subjects were seated at 60 cm viewing distance from an IBM-compatible 
computer with a 72-Hz, 17-inch colour monitor. The task was programmed using Inquisit 
software (Millisecond Software, 2001, Version 1.33). At the start of each separate trial, 
subjects were instructed to look at a fixation cross that was displayed for 1000 ms in the 
middle of the computer screen. Thereafter, two emotional faces were presented in the upper 
and the lower half of the screen, one picture surrounded by a grey frame and one by a black 
frame. At each trial, subjects had to evaluate the valence (positive or negative) of the 
emotional expression of the target picture in the grey or black frame (randomized across 
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subjects) by pressing one of two corresponding keys and had to ignore the distractor picture. 
In this multi-stimulus task, a complete NAP sequence includes two separate trials: a prime 
and a probe trial, both trials being separated by an intertrial interval of 1000 ms (+ 1000 ms 
fixation cross). Importantly, participants were not aware of this difference between prime and 
probe trial. However, within experimental conditions, distractors in the prime trial correspond 
with the emotional valence of targets in the probe trial. Due to this manipulation, the negative 
affective priming effect can be measured, involving a slowdown in responding to an item that 
has previously been inhibited, a valid index of inhibitory functioning toward affective 
material. This delay in responding is not expected within control conditions, in which there is 
no similarity between prime and probe. Table 2 provides an overview of the different 
conditions used in the NAP task.  
Subjects first completed 32 practice trials, followed by a sequence of 256 test trials, 
divided into 8 blocks of 16 prime and probe trials. The sequence of trials within the blocks 
was randomized, as was the spatial position of the target and distractor. The entire task lasted 
approximately 20 minutes. The 88 coloured pictorial stimuli used in this paradigm were 
carefully selected on valence and arousal ratings based on a prior validation study of the 
Karolinska Directed Emotional Faces database (Goeleven et al., 2008). In the present task, 33 
happy, 33 sad and 22 neutral faces were presented in random order. The neutral faces were 
used as distractors in the probe trials. Facial expressions were 5 cm wide by 5.5 cm high and 
were surrounded by a 3 mm coloured frame. Responses to prime and probe trials were 
recorded, but only responses to the probe trials were analyzed.  
 
3. Results 
For all analyses the significance level was set at an alpha level of 0.05. Analyses were 
conducted with SPSS 12.0.  
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3.1. Short-term effects of rTMS on mood and attention 
Mean mood ratings reported before (Tpre), immediately (Tpost) and 30 min after (Tpost30) 
terminating the first rTMS session (stimulation: active or sham) are summarized for each 
VAS in Table 3. Due to missing values on the VAS reports, two subjects were removed from 
analysis. Separate analysis of variance (ANOVA), with repeated measures (multivariate 
approach) for each VAS scale showed no main effects for stimulation on reports of anger (F < 
2) or for the other mood scales (all Fs < 1). No significant overall effects of time were found 
on reports of fatigue (F(1,11) = 2.95, P = 0.1), anger (F(1,11) = 2.40, P = 0.14), depression 
(F(1,11) = 2.02, P = 0.18), vigour and tension (Fs < 1). Finally, also the crucial interaction 
effects between stimulation and time did not reach significance (all Fs < 1.5). These results 
indicate that one single session of rTMS had no effect on mood.  
An ANOVA with valence (negative vs. positive), stimulation (sham vs. rTMS) and time 
(Tpre vs. Tpost30) as within-subject factors was performed on the NAP scores (individual mean 
reaction times in the experimental condition minus individual mean reaction times in the 
control condition) to examine immediate effects on the attentional processing of emotional 
information. A positive NAP score indicates effective inhibition of emotional information, 
whereas the smaller this score, the more inhibitory control becomes impaired. Contrary to our 
expectations, the three-way interaction effect between valence, stimulation and time was not 
significant (F < 1). We also could not demonstrate a significant main effect of stimulation or 
time (Fs < 1), nor did we find any significant two-way interaction (all Fs < 1.5). However, a 
near significant main effect of valence was found, F(1,13) = 3.80, P = 0.07, revealing a more 
effective inhibitory control for positive facial expressions (Mean =  36 ms) compared to the 
negative faces (Mean = - 0.45 ms). To conclude, these results indicate that one single session 
of rTMS also had no immediate effect on the attentional processing of emotional information. 
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However, we could demonstrate that depressed patients showed overall lower inhibition for 
negative as compared to positive faces. 
 
 
3.2. Treatment response 
After two weeks of rTMS treatment the whole patient group showed an overall reduction 
of 43.8 % of their scores on the HAMD and a reduction of 21.7 % on the BDI. Nine out of 
fourteen patients (64.3%) showed a reduction of more than 50 % of their scores on the 
HAMD. This way, patients were divided into two groups: responders and non-responders. 
Individual ratings on the HAMD and BDI for responders and non-responders, group means 
before and after rTMS treatment and the mean change percentage on the HAMD and BDI for 
each group are presented in Table 4. 
Examination of changes in BDI scores using a 2 X 2 ANOVA with time (Tpre vs. 
Tposttreatment) as within-subject variable and treatment response (responders vs. non-responders)  
as between-group factor revealed a main effect of time (F(1,12) = 10.00, P < 0.01) which was 
indicative of a significant decrease in depressive symptoms after two weeks of rTMS 
treatment across patients. Moreover, we also established a significant main effect of treatment 
response (F(1,12) = 9.09, P = 0.01) as well as a two-way interaction effect between treatment 
response and time (F(1,12) = 8.89, P = 0.01). Non-parametric tests were used (due to the 
small sample sizes) to further investigate this effect within groups of responders and non-
responders (Wilcoxon Signed-Rank test). Within the group of responders, significant lower 
BDI scores were reported after treatment compared to baseline (z = 2.67, P < 0.01), whereas 




3.3. Effects of rTMS treatment on attention 
To examine the effects of rTMS treatment on measures of inhibitory processing of 
emotional information, an ANOVA with valence (negative vs. positive) and time (Tpre vs. 
Tposttreatment) as within-subject factors and treatment response (responders vs. non-responders) 
as between-subject factor was performed on the NAP scores. Pre-measures of inhibitory 
control were for each subject based on their first administration of the NAP task (which was 
either before active or sham stimulation). Analyses revealed a near significant three-way 
interaction effect (F(1,12) = 3.58, P = 0.08). No other main effects or interactions were 
significant (all Fs < 1.6).  
In order to further explore the established three-way interaction, changes in attentional 
processing were investigated within groups of responders and non-responders, using non-
parametric tests (Wilcoxon Signed-Rank test). Within the group of responders, mean NAP 
scores for negative information increased significantly after HF-rTMS treatment (Mean Tpre = 
-87.77 ms vs. Mean Tposttreatment = 5.92 ms) (z = 1.60, P = 0.05 – one tailed). Contrary, no 
significant changes in inhibitory control for negative information were found in the non-
responders (Mean Tpre = -1.09 ms vs. Mean Tposttreatment = -76.18 ms) (z = 1.21, P = 0.11 – one 
tailed). In both groups, no significant changes in inhibitory control for positive information 
were found (z < 1).  
 
3.4. Correlation of clinical mood changes and changes in attentional processing 
In order to investigate whether improvements in depressive symptoms after HF- rTMS 
treatment were associated with changes in the inhibition of emotional information (i.e. 
posttreatment-measures minus pretreatment-measures of the inhibition scores for sad and 
happy facial expressions), Pearson correlation coefficients were calculated over the whole 
group.  
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A significant positive correlation was found between changes in BDI scores and changes 
in inhibition scores for sad faces (r = 0.64, P < 0.05), indicating that improvements in mood 
after treatment were associated with improvements in the inhibition of negative information. 
However, examining correlations between changes in BDI scores and changes in inhibition 
scores for positive faces, no significant results were found (r = 0.04, P = 0.88).  
 
4. Discussion 
The present pilot study aimed at offering a first glance at the potential effects of left 
dorsolateral prefrontal HF-rTMS on the attentional processing of emotional information in a 
sample of depressive patients both immediately after cessation of stimulation and at the end of 
a two week treatment period. Two important findings were established. A single session of 
HF-rTMS did not result into improved inhibitory processing of negative information nor into 
significant mood improvements. However, at the end of a treatment period of two weeks, in 
most of the patients, a decrease in depressive symptoms was found to be associated with 
improved inhibitory control for negative information. These results will be discussed in more 
detail below.  
 In line with several previous reports (Avery et al., 2006; Rachid and Bertschy, 2006; 
Bortolomasi et al., 2007; Herwig et al., 2007; O’Reardon, 2007) this study was able to 
demonstrate a mean reduction in scores on the HAMD scale of 43.8 % after two weeks of 
rTMS treatment. For more than half of our depressive patient sample (64 %) this implicated a 
reduction of more than 50 % of their scores, with beneficial effects of rTMS treatment also 
reported on self-report measures of depressive symptoms (i.e. a mean change of 21.7 % on the 
BDI). The high percentage of mood improvement in this depressive patient sample - 
compared to previous studies investigating mood effects after rTMS treatment (e.g. Couturier, 
2005) - can possibly be attributed to some methodological advantages of the present study. 
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First, a more intensive treatment protocol was used compared to prior studies (e.g. 
Koerselman et al., 2004), with high stimulus frequencies (10 HZ), high stimulus intensities 
(motor threshold above 110 %) and more and frequent pulses (1560 pulses per session), 
probably having greater antidepressant potency. Secondly, apart from the potential dose-
response effect, the higher response rate in the present study may also be attributed to the use 
of the MRI guided identification procedure of the left DLPFC. This method allowed taking 
variability in head size and shape into account in order to prevent missing the precise 
stimulation location of the left DLPFC.  
Although clear antidepressant effects were established after two weeks of rTMS 
treatment, the present study was unable to demonstrate similar positive mood changes 
immediately after one single session of rTMS. The present results are in contrast with 
previous findings of acute mood elevations after a single rTMS session in subjects 
experiencing major depression (Szuba et al., 2001), yet, these results have not been replicated 
to date. Conversely and in line with the present findings are results from recent studies 
examining immediate mood effects of rTMS in healthy volunteers. These studies also failed 
to demonstrate significant mood changes immediately after cessation of stimulation 
(Mosimann et al., 2000; Baeken et al., 2006), stating that one stimulation session may be too 
short to induce changes in the neurotransmission related to antidepressant response.  
Apart from the investigation of possible antidepressant mood effects of rTMS treatment, 
this pilot study was the first to additionally evaluate the impact of HF-rTMS over the left 
DLPFC on the attentional processing of emotional material. In line with previous cross-
sectional research of inhibitory functioning in depressive patient samples (Linville, 1996; 
Joormann, 2004; Goeleven et al., 2006), this study was able to demonstrate a pattern of results 
indicative of an impaired inhibitory control for sad facial expressions before HF- rTMS 
treatment as compared to positive information. This disturbance in the attentional processing 
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of negative information in depressive patients is not a unique finding and has already been 
reported within a number of recent studies reliably demonstrating maintained attention 
towards depression-related information and difficulties in disengaging attention away from 
emotional information with a negative content (e.g. Koster et al., 2005; Leyman et al., 2007).  
However, when evaluating the immediate effects of one single session of rTMS on this 
dysfunctional attentional processing, no instant improvements in inhibitory control were 
found, contrary to our expectations based on recent reports of enhanced top down attentional 
control (Vanderhasselt et al., 2006a, 2006b, 2007) and immediate changes in the inhibitory 
processing of negative information after prefrontal HF- rTMS in healthy volunteers (Leyman 
et al., in press). Yet, based on theoretical assumptions made by cognitive theories of 
depression (e.g. Beck et al., 1979), a possible explanation for these null results can be 
proposed. According to Beck (2008), impairements in attentional functioning and inabilities 
to filter out negative information are not just simple state markers of depression, but may 
remain present beyond episodes of depression as also reported in recent research (e.g. 
Joormann and Gotlib, 2007). This continuous cognitive inflexibility is likely to be associated 
to functionally related brain structures such as the DLPFC that may not be suscebtible to 
immediate modifications but nonetheless can be targeted by means of repeated transcranial 
stimulation (e.g. Luborzewski et al., 2007). Contrary, inducing changes in blood flow and 
regional metabolism within prefrontal brain regions in groups of healthy subjects might lead 
to immediate, yet transitory changes in cognitive functioning. Based on this reasoning, future 
research should aim at continuously monitoring inhibitory processing and accompanying 
changes in brain activation patterns (eg. using fMRI) during the entire course of rTMS 
treatment in order to shed light on possible causal effects.  
Finally and perhaps the most important finding of the present study was that, within the 
group of participants who reported significant mood improvements after two weeks of HF- 
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rTMS treatment, their disturbed inhibition of negative information also improved 
significantly. These improvements were not established within our group of non-responders, 
nor where they found for positive information processing. Moreover, positive changes in 
inhibition scores for sad faces were significantly correlated with decreases in scores on the 
BDI. The present results are consistent with previous findings of improvements in general 
cognitive performance after rTMS treatment in depressive patient samples (Fabre et al, 2004; 
Hausmann et al., 2004; O'Conner et al., 2005; Schulze-Rauschenbach et al., 2005) and extend 
these positive effects to the processing of emotional material. Importantly, because improved 
inhibitory processing of negative information was only established in those patients who 
showed a significant antidepressant effect after treatment, our results are also indicative of the 
possibility that rTMS-induced mood improvement may to some extent be related to 
improvements in cognitive functioning.  
Although the above findings are promising, some important limitations of the present pilot 
study need to be addressed.  
First, this study used an open trial of depressed patients. Therefore, because of the absence 
of a control group within the multi-session part of the design, possible placebo responses or 
practice effects on task performance cannot be excluded. Moreover, due to the absence of a 
control group, the established mood improvements after two weeks of rTMS treatment in nine 
of our depressed participants could have been a simple reflection of normal mood 
improvements over time. This may cause a need for appropriate caution in interpreting the 
present findings. However, because our study sample almost completely consisted of 
medication-resistant depressive patients who were already confronted with multiple failures 
of antidepressant treatment trials in the past and reported long periods of depression, 
spontaneous responses would be unexpected. Furthermore, administering placebo rTMS 
during a period of two weeks in a comparable sample of treatment-resistant depressive 
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patients, who consequently also have to undergo a washout of antidepressant medication, was 
not feasible from an ethical point of view.  
A second important limitation was the small sample size involved in the present study. 
Due to this limitation we were unable to check, using regression analysis, whether changes in 
mood after rTMS treatment remained when controlling for changes in inhibitory processing of 
emotional information. In other words, this pilot study was unable to provide evidence of 
specific responder characteristics, related to the attentional processing of emotional 
information that might be predictive of future treatment response. Therefore, in order to 
elucidate this question, future research should aim at replicating this study using larger sample 
sizes. Former research has already been conducted in determining whether specific 
biographical, clinical or psychopathological parameters are associated with the antidepressant 
response to rTMS (Brakemeier et al., 2007), however, not specifically focussing on this 
important cognitive vulnerability marker.  
In conclusion, although the data presented in this study are preliminary and await future 
replication, due to the small sample size and absence of a placebo control condition, this pilot 
study was the first exploring possible effects of rTMS treatment on the dysfunctional 
inhibitory processing of negative information, a frequently reported cognitive bias underlying 
the onset and recurrence of major depressive disorder. Future research involving larger 
numbers of patients and including a sham-controlled condition is needed to further investigate 
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Table 1. Demographic and clinical patient characteristics at baseline. 
 





Gender ratio (M/F) 4/10 
Hamilton Depression Score (HAMD) 23.5 (4.31) 
Beck Depression Inventory (BDI-I) 31.71 (7.92)
 
Age at onset (years) 34.07 (11.36) 
Duration of current depressive episode (years) 4.5 (4.91) 
% Hospitalisation 64%  
% High suicide risk* 43% 
Note.  Standard deviations are shown in parentheses. * Based on criteria from the Mini 
International Neuropsychiatric Interview (A high suicide risk comprises of ‘making plans to 
commit suicide’ or ‘tried to commit suicide’ or a combination of ‘thoughts of suicide’ and 
‘past suicidal attempts’). 
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Table 2. Control and experimental conditions for negative and positive trials in the NAP task 
 Negative trials Positive trials 
 Control Experimental Control Experimental 
Prime Trial     
  Distractor + - - + 
  Target + + - - 
Probe Trial     
  Distractor N N N N 
  Target - - + + 
+ happy facial expression, - sad facial expression, N neutral facial expression. 
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Table 3. Mean ratings and standard deviations for the VAS measures before (Tpre), 
immediately (Tpost) and 30 min after (Tpost30) rTMS (active or sham stimulation). 
 
 Active (N = 12)  Sham (N = 12) 
 
 Tpre Tpost Tpost30  Tpre Tpost Tpost30 
VAS        
Depression 5.89 (3.17) 5.46 (3.61) 5.92 (3.52)  6.19 (3.17) 5.08 (3.30) 5.21 (3.40) 
Anger 1.66 (2.04) 0.87 (1.19) 0.85 (0.91)  1.20 (1.46) 0.53 (0.58) 0.54 (0.58) 
Tension 5.03 (2.98) 4.21 (3.71) 4.36 (3.60)  4.38 (2.88) 4.30 (3.24) 4.51 (3.16) 
Fatigue 6.33 (3.40) 6.91 (3.06) 7.77 (2.78)  7.19 (1.88) 6.98 (1.13) 7.41 (2.48) 




Table 4. Individual scores and group means on the Hamilton Depression rating scale 
(HAMD) and Beck Depression Inventory (BDI-I) before and after rTMS treatment for 
responders and non-responders.  
 
 
HAMD  BDI-I 
 




 Pre –  
rTMS 
Post –  
rTMS 
Responders (n = 9) 
 
     
1 21.0 6.0  23.0 17.0 
2 26.0 9.0  38.0 23.0 
3 27.0 6.0  17.0 6.0 
4 27.0 10.0  26.0 21.0 
5 25.0 8.0  33.0 10.0 
6 27.0 12.0  41.0 16.0 
7 20.0 4.0  31.0 13.0 
8 12.0 3.0  33.0 26.0 




















Non-responders (n = 5) 
 
     
10 29.0 34.0  49.0 40.0 
11 23.0 17.0  32.0 36.0 
12 20.0 11.0  24.0 36.0 
13 25.0 16.0  33.0 23.0 


















Note. Standard Deviations are shown in parentheses. 
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